Alnylam Pharmaceuticals, Inc. (ALNY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Alnylam Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Alnylam Pharmaceuticals, Inc. (ALNY) has returned -16.79% so far this year and 22.54% over the past 12 months. Looking at the last ten years, ALNY has achieved an annualized return of 17.71%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Jun 1, 2004, ALNY's average daily return is +0.13%, while the average monthly return is +2.66%. At this rate, your investment would double in approximately 2.2 years.

Historically, 54% of months were positive and 46% were negative. The best month was Jun 2024 with a return of +63.7%, while the worst month was Oct 2016 at -47.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ALNY closed higher 51% of trading days. The best single day was Jul 16, 2012 with a return of +53.0%, while the worst single day was Oct 6, 2016 at -48.5%.

Alnylam Pharmaceuticals, Inc. has an annualized alpha of 25.60%, beta of 1.09, and R² of 0.13 versus S&P 500 Index. Calculated based on daily prices since June 02, 2004.

• This stock captured 206.02% of S&P 500 Index gains and 138.74% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.13 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ALNY ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Alnylam Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alnylam Pharmaceuticals, Inc. was 83.58%, occurring on Oct 3, 2011. Recovery took 439 trading sessions.

The current Alnylam Pharmaceuticals, Inc. drawdown is 32.64%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Alnylam Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Alnylam Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.